GlassScriptPhysician profile
Mladen Nikolic
NPI 1144736927
$2,360.22
in general payments reported to CMS, 2019-2025
20 companies · $912 in 2025
The $912 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $222 · 2023: $308 · 2024: $784 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,005.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $492.33 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $337.86 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $279.71 | 2024-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $226.53 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Takeda Pharmaceuticals U.S.A., INC. | $200.08 | 2022-2024 | Trintellix |
| Abbvie INC. | $163.04 | 2024-2025 | |
| Exact Sciences Corporation | $155.09 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $98.26 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $85.12 | 2023-2025 | Airsupra, Farxiga |
| Dynavax Technologies Corporation | $51.18 | 2024-2025 | Heplisav-B |
| Pfizer INC. | $48.93 | 2024-2025 | |
| Daiichi Sankyo INC. | $45.39 | 2024-2025 | Injectafer |
| Abbott Laboratories | $39.64 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.35 | 2024-2025 | Xifaxan |
| Microtransponder, INC. | $19.49 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $17.70 | 2024 | |
| Si-Bone, INC. | $17.53 | 2024 | |
| Idorsia Pharmaceuticals US INC | $17.48 | 2024 | Quviviq |
| Merck Sharp & Dohme LLC | $16.01 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Currax Pharmaceuticals LLC | $13.50 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mladen Nikolic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.